MARKET

RCUS

RCUS

Arcus Bioscience
NYSE
25.45
+0.19
+0.75%
After Hours: 25.74 +0.29 +1.14% 18:42 12/05 EST
OPEN
25.44
PREV CLOSE
25.26
HIGH
25.80
LOW
24.67
VOLUME
1.28M
TURNOVER
--
52 WEEK HIGH
26.40
52 WEEK LOW
6.50
MARKET CAP
3.10B
P/E (TTM)
-7.4155
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RCUS last week (1124-1128)?
Weekly Report · 5d ago
Arcus Biosciences Price Target Raised to $26.00/Share From $17.00 by B of A Securities
Dow Jones · 11/28 17:13
Arcus Biosciences Is Maintained at Neutral by B of A Securities
Dow Jones · 11/28 17:13
B of A Securities Maintains Neutral on Arcus Biosciences, Raises Price Target to $26
Benzinga · 11/28 17:03
Bank of America Securities Keeps Their Hold Rating on Arcus Biosciences (RCUS)
TipRanks · 11/28 13:55
Arcus Biosciences price target raised to $26 from $17 at BofA
TipRanks · 11/28 13:40
Semtech Posts Mixed Q3 Results, Joins Zhihu, Nvidia And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Benzinga · 11/25 13:01
Why Keysight Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Benzinga · 11/25 10:50
More
About RCUS
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

Webull offers Arcus Biosciences Inc stock information, including NYSE: RCUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RCUS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RCUS stock methods without spending real money on the virtual paper trading platform.